Abstract:Flanagan Balawajder and colleagues 1 conducted a cross-sectional national survey of 1028 jails from June 2022 through April 2023 to assess the availability of substance use disorder (SUD) treatment and, more specifically, medications for treatment of opioid use disorder (MOUD). In addition to the large sample size, another strength of this study was that county-level data were incorporated in analyses to better understand communities in which jails were located. Data included opioid overdoses, MOUD availability, urbanicity, and the key 16 socioeconomic factors used by the Centers for Disease Control and Prevention 2020 Social Vulnerability Index summary, such as poverty level, housing, and transportation. While results of this analysis identified that 70% of jails offered any form of SUD treatment, 44% of jails offered some form of MOUD and only 13% of jails offered at least 1 of the 3 Food and Drug Administration (FDA)–approved forms of MOUD to anyone specifically with a known diagnosis of an OUD. Additional county-level data analyses demonstrated that jails that did not offer contracted or direct health care services had 50% to 80% lower odds of offering SUD treatment or MOUD and counties that had higher Social Vulnerability Index scores had a 70% decrease in the odds of offering any SUD treatment and a 65% decrease in the odds of offering MOUD to anyone with an OUD diagnosis. These study findings have significant implications due to the large population of incarcerated individuals in the US with SUDs. As of March 14, 2024, 1 in 5 of the more than 700 000 persons in US jails were incarcerated for drug-related offenses (361 000 individuals on any given day). 2 Furthermore, persons in jail are almost 13 times more likely to have a specific treatable Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition ( DSM-5 ) SUD compared with people in the general population. 3 Additionally, there is substantial evidence that all 3 forms of FDA-approved medications for the treatment of DSM-5 moderate to severe OUD (buprenorphine, methadone, and extended-release naltrexone) are associated with reduced opioid craving, opioid use, overdose, and death, with buprenorphine and methadone being the most effective 4 ; however, only 13% of jails provided MOUD to individuals with known OUDs in this study. 1 It is well known that the lack of MOUD while in jail is associated with increased risk of death during incarceration. The number of people who died of intoxication or withdrawal while under jail supervision between 2000 and 2018 in the US increased by almost 400%, with most of these individuals dying within just 1 day of admission. 2 The Bureau of Justice Assistance, National Institute of Corrections, and American Society of Addiction Medicine have recommended that individuals with OUD who are at risk for opioid withdrawal be offered initiation and continuation of long-term MOUD in all US jails. 5 Reentry to the community after release from jail is also a critical time to intervene. There were more than 80 000 fatal opioid overdoses predominantly due to illicitly manufactured fentanyl in US communities in 2023 alone. Persons released from jail are more likely to die from overdose typically in the first 2 weeks after they reenter the community due to reduced tolerance during lack of treatment while incarcerated. 6 Thus, initiating MOUD while persons are in jail and continuing into the community is absolutely critical to save lives. 5 Methadone and buprenorphine have been shown to reduce overdose deaths by 80% in the first month after an individual is released to the community. 7 Furthermore, MOUD has other benefits through reducing HIV and hepatitis C virus acquisition and improving HIV viral suppression and hepatitis C virus cure. Providing health care in jail facilities and understanding community-level treatment availability are essential to providing MOUD and linking individuals to clinicians who can continue MOUD in the community. As shown in this study, jails that did not offer health care services were markedly less likely to offer SUD treatment or MOUD specifically. If clinicians with MOUD expertise are not available in jail facilities, telehealth with outside clinicians could be used. To improve linkage in the community, a concerted effort is needed to identify clinicians who will accept patients and can provide the form of MOUD that an individual chooses. There is a known lack of clinicians who can prescribe all 3 forms of MOUD in many communities, which thus negatively impacts the ability for persons to retain on treatment in the community. Individual-level needs that may be associated with access to and retention on MOUD in the reentry period prior to release must also be assessed in jails. As identified in this study, inadequate transpo -Abstract Truncated-

Evidence-based treatment for opioid use disorder is widely unavailable and often discouraged by providers of residential substance use services in North Carolina

Opioid Overdoses and Take-Home Naloxone Interventions: Ethnographic Evidence for Individual-Level Barriers to Treatment of Opioid Use Disorders in Rural Appalachia

Barriers and Facilitators to Accessing Opioid Agonist Therapy for Street-involved Adolescents and Young Adults in Vancouver

Treatment Utilization among Persons with Opioid Use Disorder in the United States.

Latine perspectives on the impact of family, perceptions of medication, health systems, incarceration, and housing on accessing opioid agonist therapy: A thematic analysis

"They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose

Perceived access to opioid agonist treatment in prison among people with a history of injection drug use: A qualitative study

Availability of Medications for Opioid Use Disorder in US Jails

An international comparative policy analysis of opioid use disorder treatment in primary care across nine high-income jurisdictions

Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails

Network Analysis of Medical Claims Data Suggests Network-Based, Regional Targeting and Intervention Delivery Strategies to Increase Access to Office Based Opioid Treatment (OBOT) for Opioid Use Disorder (OUD)

An emergency-department-initiated outreach program for patients with opioid use disorder is associated with an increase in agonist therapy and engagement in addictions care: a one-year cohort study

Value of Shelter-Based Opioid Treatment Among People Experiencing Homelessness

Limited acceptance of buprenorphine in recovery residences in South Florida: A secret shopper survey

Patient and navigator experiences with the opioid use disorder treatment system in Philadelphia, PA

Opioid Use Disorder Practice by Licensure Category in North Carolina

Attitudinal barriers to buprenorphine prescription and former waiver training

Underuse of Lifesaving Medications for Opioid Use Disorder in US Jails

Barriers and facilitators to implementing treatment for opioid use disorder in community hospitals

Availability and Opportunities for Expansion of Buprenorphine for the Treatment of Opioid Use Disorder

Receipt of Opioid Agonist Treatment in provincial correctional facilities in British Columbia is associated with a reduced hazard of nonfatal overdose in the month following release